CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
Lifitegrast 5% Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05505292
NCT05505292Phase 4Completed
CompareCT.gov

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

State University of New York College of Optometry·interventional·Posted Aug 17, 2022·Updated Jan 14, 2025

In Brief

A Phase 4 clinical trial evaluating Lifitegrast 5% Ophthalmic Solution and Lifitegrast Ophthalmic Solution Vehicle for Dry Eye. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals, Bausch & Lomb Incorporated

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedAug 17, 2022
Enrollment StartSep 22, 2022
Primary CompletionMay 15, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.9 years ago

Interventions

Lifitegrast 5% Ophthalmic Solutiondrug

Dosed twice a day for 8 weeks

Lifitegrast Ophthalmic Solution Vehicleother

Dosed twice a day for 8 weeks